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Abstract 
Background: Over the past few years, next-generation sequencing (NGS) has become reliable and cost-effective, 
and its use in clinical practice has become a reality. A relevant role for NGS is the prediction of response to anti-EGFR 
agents in metastatic colorectal cancer (mCRC), where multiple exons from KRAS, NRAS, and BRAF must be sequenced 
simultaneously.
Methods: We optimized a 14-amplicon NGS panel to assess, in a consecutive cohort of 219 patients affected by 
mCRC, the presence and clinico-pathological associations of mutations in the KRAS, NRAS, BRAF, and PIK3CA genes 
from formalin-fixed, paraffin-embedded specimens collected for diagnostics and research at the time of diagnosis.
Results: We observed a statistically significant association of RAS mutations with sex, young age, and tumor site. We 
demonstrated that concomitant mutations in the RAS/RAF pathway are not infrequent in mCRC, and as anticipated 
by whole-genome studies, RAS and PIK3CA tend to be concurrently mutated. We corroborated the association of 
BRAF mutations in right mCRC tumors with microsatellite instability. We established tumor side as prognostic param-
eter independently of mutational status.
Conclusions: To our knowledge, this is the first monocentric, consecutively accrued clinical mCRC cancer cohort 
tested by NGS in a real-world context for KRAS, NRAS, BRAF, and PIK3CA. Our study has highlighted in clinical practice 
findings such as the concomitance of mutations in the RAS/RAF pathway, the presence of multiple mutations in sin-
gle gene, the co-occurrence of RAS and PIK3CA mutations, the prognostic value of tumor side and possible associa-
tions of sex with specific mutations.
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Background
In recent years, major advances have been made in the 
treatment of metastatic colorectal cancer (mCRC) thanks 
to the introduction of novel therapies, such as monoclo-
nal antibodies (moAbs), which are designed against spe-
cific molecular targets [1]. Two such moAbs, cetuximab 
and panitumumab, which target the epidermal growth 
factor receptor (EGFR), have demonstrated their effi-
cacy in a subgroup of patients with mCRC characterized 
by specific molecular aberrations. However, only a small 
subgroup of patients (10% to 20%) achieves a response 
to anti-EGFR moAb single-agent treatment [2]. This 
poor response rate can be explained, in part, by activat-
ing mutations in signaling pathways downstream EGFR, 
such as in the RAS/RAF pathway [3]. Primary anti-EGFR 
resistance factors were first observed in patients harbor-
ing mutations in the genes encoding KRAS exon 2 [4]. 
Other primary anti-EGFR resistance factors have since 
been described, including additional mutations in KRAS 
(at exons 3, 4) and NRAS (at exons 2, 3, and 4) [5]. Like-
wise, mutations in the BRAF gene have been described 
as a prognostic marker and in some works as a predic-
tive factor for resistance to anti-EGFR moAb [6]. In addi-
tion, PIK3CA mutations in exon 20 have been associated 
with resistance to anti-EGFR treatment in patients with 
wild-type KRAS [7]. However, as mutations in PIK3CA 
are often associated with mutations in KRAS, the role of 
PIK3CA as an independent predictive marker of response 
to anti-EGFR needs to be confirmed.
Next-generation sequencing (NGS) can analyze sev-
eral genes simultaneously, at lower cost, person-time, 
and higher sensitivity than traditional, capillary-based 
sequencing methods. NGS has been retrospectively used 
to evaluate response to anti-EGFR therapies in mCRC 
patients [8]. In this study, we used a custom-designed 
14-amplicon NGS panel to assess the presence of muta-
tions in the KRAS, NRAS, BRAF, and PIK3CA genes in a 
single-center cohort of 219 consecutive patients affected 
by mCRC. We also investigated the clinico-pathological 
implications of those mutations and their prognostic 
impact in our cohort of patients.
Methods
NGS panel design and sequencing
Somatic hotspots in KRAS, NRAS, BRAF, and PIK3CA, 
known to be associated with mCRC, were obtained from 
COSMIC v69, and used as an input for the Ion AmpliSeq 
Designer™ online tool. Overall, 14 multiplexed primer 
pairs spanning 1556 base pairs of genomic DNA were 
designed and used, after titration experiments using two 
mCRC samples known to be KRAS mutated and wild 
types, respectively. One hundred pre-stored consecutive 
samples with known mutations in the aforementioned 
genes, previously assessed by capillary sequencing as 
part of our routine diagnostics were resequenced by NGS 
on Ion Torrent™ 314™ chips, multiplexing an average of 
8 samples per chip using AmpliSeq™ barcode kits. The 
following one hundred nineteen samples were collected 
consecutively and analyzed by NGS. Sensitivity and 
specificity of our platform, when sequencing at depth in 
excess of 1000×, were greater than 99% for FFPE samples 
with a mutant allelic fraction above 5%.
Analyses and statistics
The analysis pipeline used was as follows: in brief, runs 
were analyzed on a Dell workstation using the Ion Tor-
rent™ 3.4 alignment and calling pipeline, using hg19 
as the reference genome. To increase specificity of our 
results, as per manufacturer’s instructions, we lim-
ited our analyses to target and hotspot regions defined 
by COSMIC v69 and provided as an output by the Ion 
AmpliSeq Designer™ tool (files available upon request 
to the corresponding author). The effective presence and 
deleteriousness of found mutations, when falling outside 
the known hotspots identified by COSMIC, was con-
firmed by manual inspection of the pileups using IGV, 
and subjected to functional prediction according to a 
majority consensus of SIFT, PolyPhen2, and Mutation-
Assessor [9–11]. Mutational variables for downstream 
statistical analyses were selected using a well-established 
penalized maximum likelihood regression model imple-
mented in the R package glmnet [12]. For the comparison 
of mutational and clinical variables, we employed multi-
ple logistic regression corrected with the Firth method, 
adjusting for stage, age, anatomical site, and gender when 
appropriate. Pairwise associations between categori-
cal variables were evaluated by Fisher’s exact test, while 
differences of continuous variables among two or more 
groups were assessed using Wilcoxon or Kruskal–Wallis 
tests, respectively.
In survival analyses, we considered as our primary end-
point progression-free survival upon beginning a first 
line of chemotherapy in the metastatic setting. Survival 
curves were plotted using the Kaplan–Meier estimators, 
generated with the package survcomp [13], and p-val-
ues were calculated using the log-rank test. For survival 
analyses including more than one variable, a stepwise 
backward–forward Cox proportional hazards regression 
model was employed, starting from all clinical and patho-
logical variables described above, until minimization of 
the Akaike Information Criterion was achieved (package 
MASS) [14].
Multiple correspondence analysis (MCA) was per-
formed using the package FactoMineR (http://facto miner 
.free.fr/conta ct/index .html), after categorizing variables 
as described, and results were represented with ggplot2 
Page 3 of 10Isnaldi et al. J Transl Med          (2019) 17:137 
[13]. The mutual exclusivity and lollipop plots in Fig.  4 
were generated using the online tools OncoPrinter and 
MutationMapper [15, 16]. All statistical analyses were 
conducted within the R environment for statistical com-
puting [17].
Quantification of rare somatic cancer mutations using 
digital PCR
We validated using digital PCR (dPCR) assays co-occur-
ring somatic mutations identified in KRAS (G12S, G12 V, 
G12I, G12C, G12F, G12D, G15S, G13C), NRAS (G13S), 
BRAF (S467L), PIK3CA (G1050S). The target selection 
was based on the prevalence of mutational co-occur-
rences in our set as well as on the commercial availabil-
ity of pre-validated  TaqMan® SNP Genotyping Assays. 
These are single-tube assays containing dPCR primers 
and a probe for both the wild-type and mutant alleles. 
We prepared a reaction mix for each sample for two tech-
nical replicates (2 chips): 4  μL of DNA (20  ng/µL) with 
11.7  μL nuclease-free water, 17.4 μL QuantStudio™ 3D 
Digital PCR Master Mix, 1.7 µL Custom  TaqMan® SNP 
Genotyping Assays (20×). The dPCR reaction was loaded 
onto a QuantStudio™ 3D Digital PCR Chip v2, and PCR 
was performed using the ProFlex 2× Flat PCR System 
with the program outlined in Additional file 1: Table S1. 
We analyzed the chips using the QuantStudio™ 3D Digi-




Over 24  months, 264 specimens from colorectal can-
cer (CRC) patients were brought to our laboratory for 
KRAS, NRAS, and BRAF characterization (see Addi-
tional file  1: Figure S1). Per protocol, PIK3CA hotspots 
regions were also assessed in the current study, but not 
reported to the oncologist in charge of the patient when 
bearing mutations of potential pathological significance. 
Of 264 samples that derived all from the primary tumors, 
45 were not assessed because there was no indication for 
RAS testing (non-metastatic patients). Samples from 219 
patients were then analyzed with NGS. No sample failed 
NGS testing, although we had to re-extract tumor DNA 
in 13 cases due to poor material quality, and we had to 
generate amplicon libraries twice in 10 cases because 
of experimental failures along the library preparation 
pipeline.
Patient characteristics are reported in Additional file 1: 
Table  S2. Median age was 70  years (interquartile range 
61–76), 52% patients of the analyzed cohort were male, 
and 69% of neoplasms with available stage data (n = 156) 
pertained to the left colon, with most patients presenting 
with a large (T3 or greater), node-positive tumor at first 
diagnosis. Microsatellite staining by immunohistochem-
istry was available for 113 patients of the total population 
and showed 9 patients (8% of the assessed cases) with 
loss of MLH1 (8 patients), MSH6 (1 patient), MSH2 (no 
patients). These demographic and anatomopathologi-
cal features were well balanced according to sex, and in 
line with the epidemiologic characteristics of the mCRC 
patients diagnosed in our region. The relatively high 
median age is indeed in line with the patients referring to 
our hospital, which is situated in the region hosting the 
oldest population in Europe. Outcome data of patients 
were available for 101 patients of the entire population.
Unbiased detection of clinically relevant mutations 
in clinical‑practice NGS
Of 219 assessed samples analyzed, 143 (65%) presented 
at least one deleterious mutation in any of the four 
sequenced genes. The number of patients with mutations 
in a single gene was 109; with two mutations, 31; and with 
three mutations, 3. Mutations were not detected in any of 
the KRAS, NRAS, BRAF, and PIK3CA genes (quadruple 
mutation-negative patients) in 76 (35%) tumors.
We identified 104 (47%) tumors with KRAS muta-
tions, including one tumor with three KRAS p.G12C, 
p.G12V, and pG13C mutations and six tumors with 
two KRAS mutations p.G12V and p.G15S; pG12S and 
p.G12V; p.G12D and p.V9F; p.G12S and p.A59E; p.G12D 
and p.T58I; p.G12C and p.G13D. The mutations were 
located in exon 2 in 92 tumors (42%), exon 3 in 7 tumors 
(3.2%), and exon 4 in 8 tumors (3.6%). p.G12D, p.G12V, 
and p.G13D were the most common KRAS mutations in 
our cohort of colorectal cancers (see Fig.  1). Mutations 
located outside exon 2 were observed in 19 tumors (8%).
Fifteen tumors (7%) harbored a NRAS mutation. Seven 
mutations (3%) were located in exon 2 and 8 (4%) were 
located in exon 3. No mutations were found in exon 4. 
We found four NRAS p.G12C, p.G12D, p.G12V muta-
tions in codon 12, three mutations p.G13D, p.G13R, 
p.G12S in codon 13, seven mutations p.Q61 K, p.Q61R in 
codon 61, and one mutation p.G60E in codon 60.
Twenty-eight tumors (13%) harbored a BRAF muta-
tion including one tumor with two BRAF mutation 
p.S467L and p.V600M. Twenty-three mutations (10%) 
are located in exon 15 and six mutations (2.7%) were 
located in exon 11. p.V600E was the most common muta-
tion for BRAF, since it was found in 20 tumors (9%). One 
tumor harbored an unusual p.V600M mutation with del-
eterious effect. Eight tumors (3.6%) harbored non-V600 
mutations.
Thirty-three tumors (15%) harbored a PIK3CA muta-
tion including one tumor with two PIK3CA muta-
tions p.D725  N and p.H1047Y. Twenty mutations were 
located in exon 9 (9%), 8 mutations in exon 20 (3.6%), 
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and 6 mutations in exon 13 (2.7%). Three codons (p.E542, 
p.E545, and p.H1047) account for 26 of 33 PIK3CA muta-
tions (78%). Only three tumors (1.3%) were characterized 
by a single PIK3CA mutation without any concomitant 
alterations in the assessed genes.
Associations between genetic alterations and biological 
features
Sixty-eight (31%) tumors were located in the right colon 
and 151 (69%) tumors were located in the left colon. 
Quadruple mutation-negative tumors were observed 
in 13 right-sided colorectal cancers compared to 49 
left-sided colorectal cancers (19 vs 41%, p = 0.001). 
Right-sided colorectal cancers have had a significantly 
higher incidence of mutations in BRAF (Additional 
file 1: Table S3, 8% vs 5%, p = 0.0001). Even though MSI 
staining was available in 113 of 219 patients, we found 
7 patients (6%) with BRAF mutations and MSI status. 
Tumors with BRAF mutations were more frequently 
associated with microsatellite instability (6% vs. 2%, 
p = 0.0009). KRAS mutations were more frequent in 
females than in males (26% vs. 22%, p = 0.0460), as were 
BRAF mutations (8% vs 5%, p = 0.0269). In order to 
explore in an unbiased way the associations of the RAS/
RAF pathway with clinical and pathological variables 
in colorectal cancer, i.e., stage, tumor site, nodal status, 
sex, and age, we used multiple correspondence analysis 
(MCA). MCA is a multivariate statistical method akin 
to principal component analysis but suited for categori-
cal data; as a result, we reduced our variables of interest 
to two dimensions, which explain the largest fraction 
of the variance observed in our data set. Clinical and 
pathological variables together with KRAS, NRAS, 
BRAF, and PIK3CA status were projected as vectors in 
a space defined by those two dimensions (see Fig.  2). 
The position of the variable categories in this two-
dimensional space reflects their mutual associations, 
with no a priori assumption on the underlying struc-
ture of the data. We observed that tumors with BRAF 
mutations fell in proximity of “older age” and “right 
colon side”. In contrast, RAS mutations clustered with 
PIK3CA mutations, “younger age”, and “female sex”. In 
summary, by both MCA analysis and classic statistical 
tests we could observe two groups of patients enriched 
in specific mutational and clinico-pathological features 
(“BRAF mutations”, “right side”, “old age” in group 1 and 
Fig. 1 Map of type of mutations and their mutual relations. Top: bar plot of mutational frequency for each gene. Right side: bar plot of number of 
mutations for each patient. Main figure: mutual relationship of mutational events by patients
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“RAS mutations”, “PIK3CA mutations”, “younger age”, 
and “female sex” patients in group 2).
Coexistence of mutations in mutually exclusive genes 
revealed by clinical practice NGS
We found 34 tumors (15%) with concomitant mutations 
within KRAS, NRAS, BRAF, and PIK3CA genes. Thirty-
one tumors presented concomitant mutations in two 
genes; three tumors presented concomitant mutations 
in three genes including one tumor with BRAF, NRAS 
and PIK3CA concomitant mutations and two tumors 
with BRAF, KRAS, and PIK3CA concomitant mutations. 
Concomitant KRAS mutations were observed in 23 of 33 
PIK3CA-mutated tumors (63%), 2 of 15 NRAS-mutated 
tumors (13%), and 4 of 29 BRAF mutated tumors (13%). 
Tumors with a PIK3CA mutation showed a significantly 
higher incidence of concomitant mutations (90%) as 
compared with tumors with KRAS (26%) or BRAF (28%) 
mutations. KRAS and PIK3CA tended to be concurrently 
mutated, in a statistically and biologically significant 
fashion (OR = 2.97, 95% CI 1.27–7.40, p value = 0.0076, 
see Table 1).
Concomitant KRAS, BRAF, or NRAS mutations were 
detected in 18 of 21 tumors (85%) with a PIK3CA exon 9 
mutation and in eight of 8 tumors (100%) with a PIK3CA 
exon 20 mutation. Moreover, we found tumors with mul-
tiple mutations in the same gene including six tumors 
with two KRAS mutations, one tumor with three KRAS 
mutations, and one tumor with two BRAF mutations. Of 
these, two tumors harbored two KRAS mutations in the 
same codon. This combination of multiple mutations in 
the same gene highlighted by different allelic frequency is 
reported in Table 2.
Survival analyses
We collected clinical data concerning progression-free 
survival (PFS) and type of chemotherapy for 101 patients. 
Out of these, 75 underwent first-line chemotherapy. In 
particular, 24 patients were treated with a combination 
of fluorouracil-based chemotherapy and an anti-EGFR 
moAb (either cetuximab or panitumumab), 26 under-
went a similar backbone chemotherapy regimen with 
anti-VEGF moAb (bevacizumab), and 25 received a 
chemotherapy-only first-line therapy (either single-agent 
capecitabine or fluorouracil or combination with iri-
notecan or oxaliplatin). Tumor side (simplified as left for 
rectal, sigmoid, and descendant; and right for ascendant 
or transverse) was available for 67 patients. Information 
concerning tumor side, mutational status, and type of 
chemotherapy were available for 63 patients.
By univariate analysis, BRAF-mutant patients (N = 7) 
had a shorter PFS compared with KRAS/NRAS mutant 
patients (N = 40, hazard ratio—HR = 3.58, 95% con-
fidence interval—CI 1.48–8.66), and wild-type ones 
(N = 32, HR = 3.44, 95% CI 1.42–8.30) (p-value = 0.0073, 
logrank test, two-sided)—see Fig.  3a. The worse prog-
nosis associated with mutated BRAF mutation was 
Fig. 2 Multiple correspondence analysis (MCA) defines underlying 
the structure of clinical and pathological associations in the KRAS, 
NRAS, BRAF, and PIK3CA genes in mCRC. x- and y-axes represent the 
first and second dimension (Dim.1 and Dim.2) of the MCA analysis 
performed on clinical and pathological data from 219 mCRC patients 
collected in our center. In particular, we found a statistically significant 
association of RAS mutations with sex, young age and tumor site 
(lower left region) and BRAF mutations with anatomical site and old 
age (upper left region)
Table 1 Mutual relations of investigated genes
Values represent odds ratios with 95% CI in parentheses, p-values are in italics if < 0.05, and highlighted with one asterisk if < 0.05, two if < 0.01, or three if < 0.001
KRAS NRAS BRAF PIK3CA
KRAS – – – –
NRAS 0.15 (0.03–0.71), 0.0065** – – –
BRAF 0.15 (0.04–0.47), 0.0002*** 0.47 (0.01–3.33), 0.6993 – –
PIK3CA 2.97 (1.27–7.40), 0.0076** 2.18 (0.47–8.03), 0.2517 1.65 (0.50–4.72), 0.3930 –
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conserved by multivariable analysis, when taking into 
account PIK3CA status (adjusted HR = 3.22, 95% CI 
1.26–8.20, p-value = 0.0142 by Cox proportional haz-
ards regression) and the interaction of PIK3CA status 
with KRAS/NRAS or BRAF status (p-value for inter-
action = 0.4620 and 0.5870 respectively)—see Fig.  3b. 
Since most PIK3CA mutations co-occurred with muta-
tions in KRAS/NRAS/BRAF (25% vs. 6%), we assessed 
whether PIK3CA status could stratify the subgroup 
of mutated patients (N = 47) into different prognostic 
groups, but this analysis yielded non-significant results 
(p-value = 0.5686, logrank test, two-sided). Since all 
PIK3CA exon 20 mutations co-occurred with RAS ones, 
we could not stratify our analyses for PIK3CA exon 9 vs. 
20 mutations. Finally, we aimed at evaluating whether 
tumor side may have prognostic significance when con-
sidered alone or by multivariable analysis together with 
BRAF status, type of first-line chemotherapy, and the 
interaction of these two variables. Indeed, right side was 
associated with worse PFS by univariate statistical assess-
ment (p-value = 0.0494, logrank test, two-sided)—see 
Fig. 4. Our Cox proportional hazards model was under-
powered for analyses with more than 4–5 degrees of 
freedom, with 44 events and 9 degrees of freedom. As 
such, our results are of exploratory interest only. Of note, 
however, tumor side was the only variable independently 
associated with a PFS, with the direction of the effect in 
agreement with the univariate log-rank test. Due to the 
limitation in power size, we do not report formal results 
concerning this latest analysis.
Discussion
In this real-world study, we characterized retrospectively 
219 consecutive cases of metastatic colorectal cancer 
using NGS in clinical practice. We explored the associa-
tion of clinico-pathological variables related to the muta-
tional status of KRAS, NRAS, BRAF, and PIK3CA, genes 
that are involved in the main pathways of different solid 
tumors including colorectal cancer. Due to the high ana-
lytic sensitivity of NGS we were able to assess the con-
comitant presence of low-frequency aberrations which 
can be assessed only by non-standard and often cumber-
some methods [18].
In our cohort, 47% of patients had a KRAS mutation 
(42% in exon 2, 7% in exons 3 and 4). Seven percent of 
patients had a NRAS mutation (3% in exon 2, 4% in exon 
3). Thirteen percent of patients had a BRAF mutation, 9% 
had BRAF V600E mutation. These percentages do not 
differ from those described in previous clinical studies 
[19].
The negative prognostic role of BRAF V600E is known, 
whereas its predictive value for response to anti-EGFR 
therapy is more controversial, partly because of the small 
number of patients with this mutation described in clini-
cal trials [6, 20, 21]. Recently, results from the SWOG 
S1406 trial, demonstrated that BRAF V600E had a pre-
dictive value for response to vemurafenib [22].
On the contrary, patients with BRAF mutations out-
side codon 600 could have different outcomes. Compared 
to patients with V600 BRAF mutations who require 
aggressive treatment [23], patients with non-V600 BRAF 
mutations appear to have an excellent prognosis [24]. 
Identification of non-V600 BRAF mutations could there-
fore lead to better stratification of mCRC patients with 
different therapeutic needs. In our cohort we identified 
8 cases (3.5%) with tumors harboring a non-V600 BRAF 
mutation. This is a non-negligible proportion of patients 
considering the epidemiology of CRC, and its clinical 
characterization by routine NGS seems a sensible goal in 
the post-marketing age of anti-EGFR moAbs.
Table 2 Patients presenting with  concomitant 
and  multiple mutations in  the  KRAS, NRAS, BRAF and/
or PIK3CA genes
aa, amino acid; AF, allelic frequency
Patient ID Gene aa substitution AF




K26-13 KRAS G12D 0.39
KRAS T58I 0.08
BRAF S467L 0.12
K60-14 KRAS G12C 0.1
KRAS G13C 0.11
KRAS G12V 0.12
K13-14 KRAS G12D 0.31
KRAS V9F 0.09
BRAF R603L 0.16
K41-14 KRAS A59E 0.27
KRAS G12S 0.08
NRAS G12V 0.07
K65-13 KRAS A146V 0.44
BRAF G466V 0.33
K168-13 KRAS G12V 0.47
KRAS G15S 0.07
K35-13 KRAS G12C 0.06
KRAS G13D 0.54
K197-13 KRAS G13V 0.46
NRAS G13S 0.06
K10-14 KRAS G12D 0.06
BRAF G466V 0.11
K176-13 BRAF S467L 0.09
BRAF V600M 0.09
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Concomitant RAS and BRAF mutations are considered 
to be rare. Indeed, data from the literature report a very 
low incidence of such event [25]. These epidemiological 
data rely however mostly on capillary sequencing find-
ings (low sensitivity) or relatively low-coverage tumor 
exome sequencing from basic-translational studies. Here, 
we found four patients (1.8%) with concomitant RAS and 
BRAF alterations. Of interest, all four patients harbored a 
non-V600E mutation, which may be suggestive of either 
a lack of functional relevance of such funding, or, more 
intriguingly, of underlying peculiar biology of KRAS/
non-V600E BRAF co-mutated tumors.
As reported by other authors [25], PIK3CA tends to be 
concurrently mutated with the other genes we studied. 
The most frequent association was with KRAS (10% in 
our cohort of patients).
The distribution of mutations according to anatomi-
cal site was in line with previous works [26]. Jensen 
et  al. [27] described BRAF mutations as more frequent 
in right colon. Likewise, mutations in KRAS tended to 
be found more frequently in such anatomical region, 
although this association was not as statistically strong 
as the one with BRAF. Furthermore, microsatellite insta-
bility was strongly related to BRAF mutations, which is a 
well-established biological phenomenon driven by BRAF 
genetic sequence [28].
The correlation between mutations and sex in mCRC 
is uncertain. In the present work, we found that muta-
tions in BRAF and KRAS were more frequently associ-
ated with female sex. Although we cannot completely 
Fig. 3 Kaplan–Meier survival analyses and forest plot according to gene mutation status. Correlation between the pathway mutations and 
progression-free survival (a). wt, wild-type; RAS mt, RAS mutated; RAF mt, RAF mutated. Forest plot of Cox proportional hazards regression with RAS/
RAF mutation status and PIK3CA. mutation status (b). p-value < 0.05 is highlighted with one asterisk
Fig. 4 Kaplan–Meier survival analyses according to anatomical site. 
Correlation between tumor side and progression-free survival
Page 8 of 10Isnaldi et al. J Transl Med          (2019) 17:137 
exclude selection biases driving such finding, we were not 
able to find any obvious explanation for this correlation. 
If proven true in future, larger epidemiological studies, 
the association of specific mutations with sex in colorec-
tal cancer would be of potential biological relevance.
By multivariate non-aprioristic approaches, we iden-
tified two distinct clinical-mutational profiles. The first 
was enriched in patients with BRAF mutations, right 
colon cancer, and advanced age, in agreement with pre-
vious findings [29, 30]. The second cluster exhibited 
mutations in KRAS and PIK3CA in younger women. As 
highlighted, this association is not clearly reported in lit-
erature, so that further analyses are warranted to corrob-
orate it and ascertain its underlying significance.
To our knowledge, only few works investigated in detail 
the concomitant presence of multiple mutations in a sin-
gle gene [31]. Here, we described several cases defined 
by this peculiar characteristic in our cohort. Although 
we assessed fewer genes compared to larger multipanel 
NGS studies [32, 33], the strength of the present work lies 
in its real-word nature: as far as we know this is the first 
report of such nature.
Hence, it is not unexpected that we could identify eight 
patients (3.5%) with more than one mutation in a sin-
gle gene. The presence of these multiple and concomi-
tant mutations, some of which at low allelic frequency, 
reflects the likely existence of subclonal populations 
within the tumor as an expression of intratumoral het-
erogeneity [34]. Currently, it is not clear whether tumor 
property could result in a more aggressive phenotype [35, 
36]. Also, whether early identification of these subclonal 
populations should influence treatment strategies is a 
matter of active debate [37].
A major value-added of our study is the assessment 
of the relationship between RAS, PIK3CA, and BRAF 
tumor mutation status with clinical response to chemo-
therapy in the metastatic setting. BRAF mutation was 
prognostic for poor progression-free survival (PFS) by 
univariate and multivariate analysis, adjusted for the 
interaction of PIK3CA status with KRAS/NRAS or BRAF 
status. PIK3CA status by itself had no ability to stratify 
subgroups of mutated patients with different prognos-
tic groups, as reported in previous works [38]. PIK3CA 
mutational co-occurrence with RAS aberrations may be 
among the reasons why the independent prognostic and 
predictive role of PIK3CA mutations in mCRC remains 
uncertain [39]. Indeed, we could not demonstrate that 
co-mutated KRAS/PIK3CA cases are endowed with dif-
ferent clinical consequences compared with KRAS-only 
mutant ones.
We did not observe significant differences for PFS in 
wild-type or RAS-mutated patients undergoing first-line 
treatment, probably due to the small number of patients 
included in the analysis. However, we were able to estab-
lish a negative prognostic value of tumor side irrespective 
of BRAF status and type of chemotherapy administered 
as first-line. Indeed, tumor side appeared as the only 
variable independently associated with PFS, as recently 
reported by other colleagues [40].
Since landscape works such as that of Galon et  al. 
[41], where an immunological score with prognostic 
value based on lymphocyte infiltration in CRC was first 
described, increasing knowledge of cancer immunity has 
been changing tumor treatment. This phenomenon has 
been particularly evident in lung cancer and melanoma, 
with the introduction of novel immune-acting drugs [42, 
43]. Currently, immunotherapy has been shown to have 
only modest efficacy in CRC, with possible exceptions in 
microsatellite-unstable tumors [44]. This modest effec-
tiveness has been in part associated with the extreme 
heterogeneity of CRC based on molecular subtypes but 
is not completely explained by them. For example, it was 
described that KRAS mutation is associated with sup-
pressed Th1/cytotoxic immunity in CRC [45], whereas 
another work demonstrated that pathway mutations 
such as those in the RAS/RAF or PI3KCA pathways are 
associated with different expression of tumor leucocyte 
fraction [46]. Hence, we suggest that in future research, 
somatic mutations in CRC driver genes be also investi-
gated in association with immune-related parameters, to 
obtain a more precise immunobiological stratification of 
patients.
We are aware of the limitations of our study. For exam-
ple, tumor microsatellite instability status was available 
for only half of our patients, and this may have contrib-
uted to the lower MSI frequency we described in our 
mCRC compared to other studies. Also, survival analy-
ses have a limited statistical power due to the absence of 
outcome data for half of our patients. Nonetheless, we 
believe that a major strength of the present work lies in 
its real-world nature and in the inherent simplicity of the 
design of our panel. As such, we were able to convey bio-
logical and clinical findings that can really be applied to 
the general population, with relevant consequences for 
clinical practice. Furthermore, our NGS panel is cancer-
type specific, fitted for a clinical context where there is 
need to maximize the cost/utility ratio of analyses for 
diagnostic and prognostication according to the char-
acteristics of CRC specimens sent to our center and to 
the scientific evidence of specific mutations. Certainly, 
reagent cost and analysis turnaround time for NGS tar-
geted panels are easy argument for extending the use of 
NGS to multicancer assays. However, it is our personal 
feeling that, outside clinical trials and cancer landscaping 
efforts, such extended panels may be of nontrivial use, 
and in certain situations could even lead to potentially 
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detrimental effects (e.g., the difficulty in clinical interpre-
tation and subsequent use of novel identified alterations). 
Broader, multicentric, more standardized approaches 
need to be implemented to properly assess the effective 
medical utility of large, multicancer NGS panels.
Conclusions
Our present research strongly supports the routine appli-
cation of NGS in the clinical practice context for the 
diagnosis of mutations in mCRC. NGS indeed leads to a 
more accurate stratification of patients benefitting from 
anti-EGFR treatment compared to commercially avail-
able non-NGS-based kits. Similarly, we provide evidence 
in clinical practice that low-frequency subclones of het-
erogeneous, yet already anti-EGFR resistant clones exist 
in primitive colorectal tumors, with strong implications 
for targeted treatment planning and design of future clin-
ical trials.
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